On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors;Zur klinischen relevanz der wirkung von clozapin auf die freisetzung von zytokinen und löslichen zytokinrezeptoren

Fortschritte der Neurologie Psychiatrie

Volumn 69, Issue SUPPL. 2, 2001, Pages

  Pollmacher Th ^a   Schuld, A ^a   Kraus, Th ^a   Haack, M ^a   Hinze Selch, D ^a,b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYTOKINE; CYTOKINE RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

AGRANULOCYTOSIS; CELL INTERACTION; CONFERENCE PAPER; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG RESPONSE; FEVER; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MYOCARDITIS; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYTOKINES; HUMANS; NERVOUS SYSTEM; RECEPTORS, CYTOKINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034814491     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (92)

1. Das wirkungsprofil eines chemisch neuartigen breitbandneuroleptikums der dibenzodiazepingruppe
2. Das klinische wirkungsbild von clozapin
3. Clozapine. A novel antipsychotic agent
4. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
5. Prospects for pharmacotherapy of schizophrenia
6. Agranulocytosis during treatment with clozapine
7. Agranulocytosis induced by certain phenothiazine derivatives
8. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States
9. Blood dyscrasias in clozapine-treated patients in Italy
10. G-CSF and the management of clozapine-induced agranulocytosis
11. Temperaturanstiege und bluteiweißveränderungen unter der therapie mit neuroleptika - Unter besonderer berücksichtigung des neuartigen dibenzodiazepin-derivates clozapin
12. The interleukin-1 family: 10 Years of discovery
13. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels
14. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight
15. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment
16. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol
17. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels
18. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors
19. Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine
20. In vivo immunomodulatory effects of clozapine in schizophrenia
21. Effects of clozapine on hematopoiesis and the cytokine system
22. Effects of clozapine on in vitro immune parameters - A longitudinal study in clozapine-treated schizophrenic patients
23. Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1
24. A molecular basis for bidirectional communication between the immune and neuroendocrine systems
25. Clozapine-induced thrombocytosis
26. Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine
27. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis
28. Do white-cell count spikes predict agranulocytosis in clozapine recipients?
29. Clozapine-induced transient white blood count disorders
30. Does eosinophilia predict clozapine induced neutropenia?
31. Effects on leukocytes after injection of tumor necrosis factor into healthy humans
32. Granulocyte and granulocyte-macrophage colony-stimulating factors
33. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men
34. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine
35. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups
36. Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia
37. Allergic myocarditis in clozapine treatment
38. Clozapine and myocarditis
39. Myocarditis under therapy with clozapine
40. Peri-/myokarditis unter clozapin (Leponex)
41. Myocarditis and cardiomyopathy associated with clozapine
42. Tumor necrosis factor in the heart
43. The role of tumor necrosis factor in the pathophysiology of heart failure
44. Toxic hepatitis by clozapine treatment
45. Concurrent agranulocytosis and acute hepatitis resulting from combination of classic neuroleptics and subsequent successful clozapine treatment
46. Dystonia and drug-induced hepatitis in a patient treated with clozapine
47. Clozapine-induced toxic hepatitis
48. Fatal acute fulminant liver failure due to clozapine: A case report and review of clozapine-induced hepatotoxicity
49. Hepatotoxicity of clozapine
50. Eosinophilia, clozapine, and pancreatitis
51. Asymptomatic pancreatitis associated with clozapine
52. Clozapine-associated pancreatitis
53. The role of cytokines in the pathogenesis of acute pancreatitis
54. Possible association of parotitis with clozapine
55. Clozapine-induced parotitis - An immunological cause?
56. Antipsychotic-induced weight gain: A comprehensive research synthesis
57. Serum leptin levels increase rapidly after initiation of clozapine therapy
58. Leptin
59. Body weight and leptin plasma levels during treatment with antipsychotic drugs
60. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-α and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine
61. A role for leptin in hemopoieses?
62. Regulation of neuronal and glial proteins by leptin: Implications for brain development
63. Tumor necrosis factor-alpha regulates secretion of the adipocyte-derived cytokine, leptin
64. Interleukins and tumor necrosis factor as inhibitors of food intake
65. Journey from cachexia to obesity by TNF
66. Tumour necrosis factor, a key role in obesity?
67. Plasma concentrations of soluble TNF-alpha receptors in obese subjects
68. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes
69. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
70. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
71. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
72. Diabetes as a result of atypical anti-psychotic drugs - A report of three cases
73. Diabetic ketoacidosis with clozapine treatment
74. Diabetic ketoacidosis associated with clozapine treatment
75. Clozapine-induced diabetic ketoacidosis
76. Diabetic ketoacidosis and clozapine
77. Clozapine monotherapy and ketoacidosis
78. Diabetic ketoacidosis from clozapine and lithium cotreatment
79. Diabetic ketoacidosis associated with clozapine treatment
80. Clozapine and associated diabetes mellitus
81. Fever: Role of pyrogens and cryogens
82. Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep
83. Schlaf und schläfrigkeit im rahmen von infektionen und im rahmen experimenteller immunmodulation beim menschen
84. Experimental immunomodulation, sleep and sleepiness in humans
85. Dose-dependent effects of endotoxin on human sleep
86. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs
87. Effects of clozapine on sleep: A longitudinal study
88. Sleep during clozapine-induced fever in a schizophrenic patient
89. Effects of antipsychotic drugs on cytokine networks
90. Cytokines and the nervous system I: Expression and recognition
91. Tumor necrosis factor: An updated review of its biology